CL-PTL-119: Double-Blind, Placebo Controlled Phase III Trial of Maintenance FANG (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) for High Risk Stage III/IV Ovarian Cancer

Administered By

Awarded By

Contributors

Start/End

  • August 1, 2015 - July 31, 2020